



IRON DEFICENCY ANEMIA



Do you suffer from
Iron Deficiency Anemia (IDA)?



Would you like to increase your **Serum Iron** and
your **Ferritin** by **50-70%** in as little as **30 days**?

With no side or adverse effects!

HERE IS HOW !



Causes of ANEMIA





IRON & FOODS

Generally, foods are **never deficient in iron!**


IRON in foods: **6-7 mg/1000 Kcal**
almost ubiquitous



MEAT/FISH: **40% heme**
60% non-heme



OTHER FOODS: **100% non-heme**




PROBLEM:

Iron is difficult to be absorbed: 1-2 mg out of 12-20 mg present in the daily diet



IRON ABSORPTION






Absorption level



*HEME
IRON*



*Absorbed at a level of
20%- 30%*



*NON HEME
IRON*




*Absorbed at a level of **5%**
(promoted by *Citric, Lactic* and
Ascorbic acids)*

Polyphenols and Tannins reduce absorption by 30%



Symptoms of Anemia





ORAL IRON SUPPLEMENTATION



Oral iron supplementation is by far the first and most frequent therapy.

Efficacy: very modest

Increase of iron parameters 10 – 30%

Results: very slow

90- 120 days, in less than 50% of patients




PROBLEMS:

It dramatically increases oxygen free radicals within the gut, which induce or significantly aggravate inflammation by causing lipid peroxidation in the colon and by increasing pro inflammatory cytokines (*IL-1, IL-6, Gamma Inf., TNF- α , IL-3, IL-4.*) **which lead to the reduction of erythropoiesis**



Inflammatory stimulus: *infection, autoimmunity, cancer, iron supplementation*

Oral Iron Supplementation induces inflammation which, on its turn, reduces Erythropoiesis



Other Common Adverse effects of oral iron

Oral iron therapy is also associated with **many side effects** such as : *constipation, diarrhoea, nausea, vomiting, abdominal pain, faintness*



diarrhea / constipation



dark stools may obscure the diagnosis of continued gastrointestinal blood loss



nausea



vomiting



upset stomach



faintness

Moreover, the **iron-enhanced oxidative stress** may lead to increase:

• Mutagenesis

• Cell Death

• Ulceration



Iron Oral therapy: failure in controlling Anemia in IBD patients

A recent study carried out at the University Hospital of Birmingham has shown that treatment with oral iron results in failure to control anaemia in 2 out of 3 IBD patients.





The failure to control anaemia in 2 out of 3 IBD patients is in part due to the side effects reported by over 50% of patients



Journal of Crohn's and Colitis (2014) 8, 876–880

Available online at www.sciencedirect.com

Iron treatment and inflammatory bowel disease: What happens in real practice?☆

Sebastian Lugg, Felicity Beal, Peter Nightingale, Neeraj Bhala, Tariq Iqbal*

Department of Gastroenterology, University Hospitals Birmingham, United Kingdom

Received 14 October 2013; received in revised form 8 January 2014; accepted 9 January 2014

KEYWORDS
Anaemia;
Inflammatory bowel disease;
Iron

Abstract

Background and aims: Iron deficiency anaemia (IDA), the most common extra-intestinal complication of inflammatory bowel disease (IBD), negatively impacts quality of life. We audited the recent practice of anaemia treatment in an unselected IBD population.

Methods: A questionnaire was distributed to adult IBD outpatients in a university hospital to assess the form and frequency of iron prescribed, duration of use, side effects, and completion of therapy. The efficacy of treatment was determined by the resolution of anaemia and change in haemoglobin from baseline.

Results: Of 87 IBD patients (60 patients with Crohn's disease, 25 with ulcerative colitis, 2 with microscopic colitis), 85 received various dosing regimens of iron tablets; 15 patients also received IV iron. Side effects were reported in 43 (51%) patients, with no clear relationship to dose prescribed and 26 (32%) patients were unable to complete the intended course. Only 36 (42%) patients completed the course of oral iron without side effects and in these patients, haemoglobin normalised in about 30%. Their median haemoglobin change was 12.5 (5.3–23.5) g/L. The median duration of treatment in those without side effects was 4.5 months, and in those with adverse effects was 2 months. Only one adverse effect was reported for IV iron.

Conclusions: Treatment with oral iron results in failure to control anaemia in 2 out of 3 IBD patients, which is likely in part to be due to the side effects reported by over half of patients. Patients failing to tolerate or adequately respond to therapy should be offered alternative treatment.

© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.



ALTERNATIVE to Oral Iron Therapy:

THE INTRAVENOUS ADMINISTRATION of iron preparations



but still serious side effects have been experienced:

- Hypersensitivity reactions
- Tachycardia
- Strong Perspiration
- Worsening of Rheumatic Syndrome
- Myalgia
- Dysgeusia
- Iron Overload



How to fix the problem?

Here is the solution!



The first iron-free «Iron Fixative!»

Simple, fast, effective and..... fully safe




Introduction: The «Meat Factor»



it is well documented that **heme-iron** contained in meat is absorbed better than non-heme iron.

It has also been shown that meat promotes as well the absorption of non-heme iron contained in other foods



This “**Meat factor**”, that promotes the absorption of non-heme iron, consists of certain carbohydrates present in the extra-cellular matrix of the muscular fibres of meat.


This has been demonstrated in vitro by using Caco-2 cells, which represent the gut mucosa.



Discovery: The « Fish Factor»




The main ingredient of **IRON CATCH** is a special type of **“Fish Factor”**, made of specific oligosaccharides from fish cartilage, that is up to 5 times more active than “Meat factor” in *increasing the **non-heme iron absorption** from foods by the enterocytes.*





The location of iron absorption

Iron is absorbed in the first part of intestine (*duodenum and jejunum*), due to the action of proteins:




DMT1
(**Divalent Metal Transporter 1**)
(*absorption*)

This protein binds Fe^{2+} , Cu^{2+} in the Lumen of the first part of intestine and **makes Fe^{2+} enter into the Enterocyte**

HEPHAESTIN (HEPH)
FERROPORTIN (IREG1 or Fpn)
(*passage from mucosa to blood*)


These proteins are **both oxydant**; by changing Fe^{2+} to Fe^{3+} allow Fe^{3+} to get out of the Enterocyte and **enter into the blood stream**, bound to Transferrin.



THE INTEGRITY OF THE MUCOSA IS FUNDAMENTAL



How Iron is absorbed into the blood stream




After entering into the Enterocyte through **DMT1**, Fe^{2+} must be oxidated to Fe^{3+} by **Hephaestin** and **Ferroportin-1**, which is the only “**exporter**” of iron into the **blood stream**, where Fe^{3+} binds to **Transferrin**. **Ferroportin** (*Fpn1*) is regulated by **Hepcidin**, a hormone produced by the liver; **Hepcidin** reduces the **iron-efflux activity of Fpn1** thereby reducing iron delivery to the blood plasma. Therefore, the interaction between **Fpn1** and **Hepcidin** controls the systemic iron.

When additional iron is not required by the organism, Fe^{2+} inside the enterocyte **binds** to Ferritin and is lost in the Intestinal Lumen when the cell desquamates.



Iron absorption: «IRON CATCH Factor»



highly enhances
non-Heme iron
absorption:
**3 to 5
times more**



Biochemical and Molecular Actions of Nutrients

Carbohydrate Fractions from Cooked Fish Promote Iron Uptake by Caco-2 Cells¹

Eun Chul Huh, Arland Hotchkiss,* Janine Brouillette,* and Raymond P. Glahn^{†2}

*Institute of Food Science, Cornell University, Ithaca, NY 14853; *U.S. Department of Agriculture/ARS, Eastern Regional Research Center, Wyndmoor, PA 19038; †U.S. Plant, Soil and Nutrition Laboratory, U.S. Department of Agriculture/ARS, Ithaca, NY 14853*

ABSTRACT The objective of this study was to isolate and characterize the meat factor(s) that enhance the bioavailability of iron using various analytical and in vitro cell culture techniques. Nonheme iron from radiolabeled iron uptake or ferritin formation in Caco-2 cells. Fish muscle was chosen as the muscle tissue of choice because of its low iron content. The primary factor(s) responsible for the release of iron from meat was isolated and characterized using size exclusion chromatography. Subsequently, cooked fish muscle fractions were tested for their ability to enhance iron uptake by Caco-2 cells. The active fractions contained negligible amounts of protein and carbohydrates. Subsequent chromatography yielded 3 active peaks that increased iron uptake 3.4- to 4.9-fold. Our results indicate that specific carbohydrates contribute to the effect of meat on iron uptake by the enterocyte. These carbohydrates may be oligosaccharides originating from glycosaminoglycans in the extracellular matrix of muscle tissue. *J. Nutr.* 134: 1681-1689, 2004.

Our results show that specific carbohydrates play a part in increasing the effect of meat on Fe captation by the enterocyte. These carbohydrates originate from glycosaminoglycans in the extracellular matrix of muscle tissue.


KEY WORDS: • meat factor • iron • in vitro digestion • Caco-2 cells • oligosaccharides



Replenishment of Fe deposits



The “*Fish-Factor*” contained in **IRON CATCH** is able to form a **complex with Fe^{2+}** , which acts as “*Heme frame*” and makes iron enter into the enterocytes, through the **DMT1**, before being “exported” to blood as **Fe^{3+}** bound to Transferrin.





Clinical studies



Three clinical studies were carried out:

• • **2 in Italy**



and

• **1 in Jordan**



on a total of **337 patients**



1st Study in ITALY



The study was carried out at the University Hospital
“Policlinico San Matteo” of Pavia



Fondazione IRCCS
Policlinico San Matteo






1st Study: enrolled patients




49 fertile women:



For each group, 2 sub- groups were planned:



With Plasma Iron <60mcg/dl



With Ferritin < 20 ng/ml

Treatment was carried out for **2 months** with measurements at
T0- T1 – T2



1st Study: results




SERUM IRON



Patients with serum iron < 60mcg/dl:

	T0	T1	%	T2	%
Serum Iron Mcg/dl	36,4± 9,8	65,3± 11,8	+ 79	57± 28,2	+58





1st Study: results




FERRITIN



Patients with Ferritin < 20ng/ml

	T0	T1	%	T2	%
Ferritin ng/ml	8,6± 4,4	13,9± 6,6	+ 61	15,5±10,5	+80



■ IronCatch
■ Placebo

Subjects with a ferritin level <20 ng/ml



Fondazione IRCCS
Policlinico San Matteo



From the above data it is easy to conclude:



When Serum Iron is low,
it increases rapidly by **79%** in just 30 days

When Ferritin is low,
it increases rapidly by **61%** in 30 days and
by **80%** in 60 days.

When Sideremia and Ferritin are **normal**,
they don't move significantly: **no risk of overload !**

The **Placebo** didn't cause any change in patients, neither for Serum Iron, nor for Ferritin.



Publication





PubMed A service of the National Library of Medicine and the National Institutes of Health

www.pubmed.gov

My NCBI [Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [Save Search](#)

Did you mean: [captafol](#) (73 items)

Display Show Sort by Send to

All: 1 Review: 0

1: [Minerva Med.](#) 2006 Oct;97(5):385-390. [Links](#)

Effect of treatment with food supplement (containing: selected sea fish cartilage, vitamin C, vitamin E, folic acid, zinc, copper) in women with iron deficiency: double blind, randomized, placebo-controlled trial.

Rondanelli M, Opizzi A, Andreoni L, Trotti R.

Unita Endocrino-Nutrizionale, Azienda Servizi alla Persona, Istituzioni Assistenziali Riunite di Pavia, Pavia, Italy.

AIM: The term iron deficiency is used to indicate a condition in which the content of iron (Fe) in the organism is low, even before the consequent reduction in erythropoiesis comes about. This clinical situation is very frequent in patients in fertile age. The therapy commonly used (Fe salts) is often poorly tolerated. The use of a food supplement containing nutrients useful for improving the bioavailability of Fe and that is well tolerated can represent a valid alternative to iron therapy. METHODS: The present study examines 49 fertile women with iron deficiency, of normal weight and not undergoing estroprogestin treatment. The patients underwent 3 assessments: basal, after 30 and after 60 days to determine their complete

Related Links

- ▶ [\[Trace nutrients in total enteral nutrition: the basal status a \[Minerva Gastroenterol Dietol. 1993\]](#)
- ▶ [The effect of long-term calcium supplementation on indices of \[Br J Nutr. 1996\]](#)
- ▶ [Treatment for iron deficiency anaemia with a combined supplementation \[Eur J Clin Nutr. 1999\]](#)
- ▶ [The impact of intensive serial plasmapheresis and iron supplementation or \[Transfusion. 2003\]](#)
- ▶ [Effect of intravenous ascorbic acid in hemodialysis patients w \[Am J Kidney Dis. 2006\]](#)
- ▶ [See all Related Articles...](#)



2nd Study in Italy



The 2nd study was carried out at the University Hospital “*Policlinico Sant’Orsola*” of Bologna



**Policlinico
S.Orsola
Malpighi**





2nd Study: enrolled patients




25 patients



11 suffering from

9 ♂ 2 ♀


CROHN'S DISEASE



14 suffering from

8 ♂ 6 ♀

ULCERATIVE COLITIS



Treatment was carried out for **4 months** with measurements at **T0- T2** and **T4**





2nd Study: results




SERUM IRON



IDA Patients suffering from IBD :

	T0	T2	%	T4	%
Serum Iron mcg/dl	26,7± 13,6	46± 27,2	+ 72	44,5± 21	+58



IronCatch[®]





2nd Study: results


FERRITIN



IDA Patients suffering from IBD :

	T0	T2	%	T4	%
Serum Ferritin μ/ml	8,5± 6,8	14,5±20,5	+ 70	14,1± 10,3	+66

+70% vs baseline



+ 66 % vs baseline

IronCatch™






2nd Study: results

HEMOGLOBIN



IDA Patients suffering from IBD:

	T0	T2	%	T4	%
Hemoglobin g/dl	10,96 ± 0,90	11,07±1,02	+ 1	11,48± 0,94	+ 5





PO Box 2345, Beijing 100023, China
www.wjgnet.com
wjg@wjgnet.com



World J Gastroenterol 2007 March 14; 13(10): 1575-1578
World Journal of Gastroenterology ISSN 1007-9327
© 2007 The WJG Press. All rights reserved.

RAPID COMMUNICATION

A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study

Andrea Belluzzi, Giulia Roda, Francesca Tonon, Antonio Soleti, Alessandra Caponi, Anna Tuci, Aldo Roda, Enrico Roda

Andrea Belluzzi, Giulia Roda, Francesca Tonon, Antonio Soleti, Alessandra Caponi, Tuci Anna, Aldo Roda, Enrico Roda, Gastroenterology Unit, University of Bologna, S.Orsola Hospital, Via Massarenti, Bologna 9 40138, Italy
Correspondence to: Belluzzi Andrea, MD, Ospedale S Orsola, UO Gastroenterologia Via Massarenti, 9-40138 Bologna, Italy. belluzzi@aosp.bo.it
Telephone: +39-51-6363873 Fax: +39-51-6363873
Received: 2006-11-12 Accepted: 2006-12-15

Key words: Ulcerative colitis; Crohn's disease; Anemia; Fish cartilage; Iron deficiency

Belluzzi A, Roda G, Tonon F, Soleti A, Caponi A, Tuci A, Roda A, Roda E. A new treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study. *World J Gastroenterol* 2007; 13(10): 1575-1578

<http://www.wjgnet.com/1007-9327/13/1575.asp>



From the above data it is easy to conclude:




Patients affected by IBD and IDA can easily increase in just 60 days:

Serum Iron by 72%

Serum Ferritin by 70%

Hemoglobin by 5% in 120 days



No side effects were recorded !




3rd Study: in Jordan



It was carried out on

263 IDA patients:



201 women

64 men



and





Their level of Ferritin was evaluated after only **30 days**
of treatment with **IRONCATH**



3rd Study: results



FERRITIN


Ferritin ng/ml	T0	T30	%
Men 	21,5	26,7	+24
Women 	7,2	12,5	+73
Total average	16,6	25,1	+ 51

In men Ferritin increases less because the basal line is much higher than in women.

Ferritin ng/ml



Ferritin ng/ml





Conclusions from the three studies



The 3 studies taken into consideration were carried out in **three different hospitals**, of **two different countries**.

The three groups of patients were also **different** ones amongst each other :



At the Pavia Hospital patients were **50** fertile **women**, affected only by **Iron Deficiency Anemia (IDA)**



At the Bologna Hospital patients were **17** **men** and **8** **women** affected by **IBD and showing IDA**



In the Jordan Study patients were numerous, **263** men and women, and the group was not homogeneous.



Final results from the three studies



Incredibly, in all the **three studies**, notwithstanding the various differences among the patient groups and the technicians making the iron measurements, the final results were quite similar:

- **Serum Iron** increased in average between **58 and 79%** in 30 days
- **Ferritin** increased in average between **61 and 70%** in 30 days

The results consolidated in **60- 120 days**

NO ADVERSE EFFECT were recorded: **fully safe!**

Iron values in **men** increase **less than in women** because their baseline is higher

Subject with **Normal Iron** value **didn't** significantly **vary**:

No risk of overdose



The Product:

THE IRON-FREE SOLUTION

The most advanced, efficacious, fastest, easiest preparation for **IDA**

The therapy with **IRONCATCH** is **100% SAFE**


- No side or adverse effects
- No contraindications
- Fast increase of iron in the body
- No risk of overload





Formulation strategy

The **MAIN INGREDIENT**: «**FISH FACTOR**»
made of a special mix of **fish oligosaccharides**




Iron-free

The «**CATALIST COMPONENTS**»:



Vitamin C & E: anti oxidants,
help protect Fe^{2+} and facilitate iron absorption
by the enterocytes




Folic acid: necessary to prevent megaloblastic anemia and
anomalies in the fetal nervous system during
pregnancy




Zn & Cu: both contribute to the correct use of iron by the
biological system.
CU is essential for Fe absorption by enterocytes
and after **gastro-resection**






Further Iron benefits in IDA : after only 1 week of treatment




Outcome		Significant benefit of iron supplementation demonstrated
Symptoms	Fatigue	✓
	Restless leg syndrome	✓
	Hair loss	✓
	Glossitis	✓
Quality of life measures	Impaired QoL	✓
	Impaired physical function	✓
	Impaired cognitive function	✓




Specially recommended when Iron Supplementaion is contraindicated like:




Gastro Resection (also *CU* is needed)



Serious Hepathopaties



Serious nephropathies



Anti Cancer Chemotherapies



Further elective recommendation for:



Vegans and Vegetarians




Endurance sport

Lactation



Pregnancy



Junior formulation




Reduction of efficacy :



IRONCATCH is active in acid environment; therefore



if an **anti-acid Product** is administered during a **meal**



IRON CATCH in **that meal** would lose part of its **efficacy**



How to use it



2 tablets a day during main meals for
2 to 4 months, depending on the subjects

and



1 tablet daily for maintenance.

IRON CATH is for everybody and it is essential for all those IDA patients for **whom** Oral Iron Therapy is contraindicated.

Active no matter which the diet is!